Strong Alliance, New Chapter Unfolds | Bloomage and Xcell Therapeutics Form Strategic Partnership to Explore the New Blue Ocean

2025.09.26

Recently, Bloomage and Xcell Therapeutics officially signed a strategic cooperation agreement, marking the establishment of a deep partnership in China’s Cell and Gene Therapy (CGT) field. Together, the two companies will promote innovation and industrial application of cell culture media technologies.

Bloomag: A Pioneer in Synthetic Biotechnology and Biomanufacturing Innovation

Founded in 2000, Bloomage is a multinational biotechnology and biomanufacturing company, and the world’s largest supplier of hyaluronic acid raw materials. Listed on the Shanghai Stock Exchange in 2019, Bloomage has built an integrated solution system spanning pharmaceuticals, medical aesthetics, nutritional science, and skin science, based on its synthetic biology manufacturing capabilities. Its products are sold in more than 70 countries, serving over 4,000 brand clients worldwide. The company has become a trusted partner for many top universities, research institutions, hospitals, and Fortune 500 companies.

In recent years, Bloomage has expanded into regenerative medicine and the cell culture media industry. In the second half of 2023, Bloomage launched its first domestically produced cell culture medium in China. Later that year, in December, the Hainan Provincial Key Laboratory for Regenerative Medicine Technology and Materials Transformation—initiated and established by Bloomage—was officially unveiled.

Xcell: A Specialist in AOF Chemically Defined Cell Culture Media

Xcell Therapeutics is the only cell culture media company listed on the Korean KOSDAQ market and one of the few in the world capable of providing a full portfolio of AOF (Animal-Origin-Free) chemically defined media. With its innovative XPorT platform technology, exceptional product performance, and internationally recognized quality—having been among the first to register a DMF with the U.S. FDA—Xcell has become a global benchmark in the CGT field.

Building the “Core Foundation” of Cell Therapy Together

Xcell brings internationally leading technologies and products, while Bloomage contributes deep market expertise, robust distribution networks, and comprehensive service systems in China. This collaboration exemplifies a strong and complementary alliance. The partnership not only grants Bloomage exclusive rights to distribute Xcell’s NK cell culture media in China but also builds on the success of their T cell media cooperation since 2024. Customer testing data has demonstrated Xcell media’s superior performance in cell proliferation and viability, laying a solid foundation of technical trust for its expansion in the Chinese market.

Empowering a Secure and Upgraded Chinese Biopharma Supply Chain

This collaboration goes beyond a conventional commercial agreement—it represents a significant step toward ensuring the security, compliance, and self-reliance of China’s biopharmaceutical supply chain. With the rapid growth of the Chinese CGT market, the demand for high-quality, animal-origin-free, chemically defined media is increasingly urgent. Leveraging its strong market network and localized service capabilities, Bloomage Biotech will accelerate the introduction of Xcell’s world-class products and technologies into China, helping domestic pharmaceutical companies advance drug innovation and industrialization.

Tapping into a Billion-Dollar Market, Building a Thriving Industry Ecosystem

According to market forecasts, China’s immune cell therapy sector could reach a market size of USD 10 billion by 2030, with culture media as a critical raw material offering immense growth potential. Against this backdrop, Bloomage and Xcell will continue deepening their cooperation, with prospects of expanding the culture media pipeline, co-developing new technologies, and even collaborating in the cosmeceutical field. This partnership marks a new starting point for Bloomage Biotech, as the two companies work together to drive the standardization and scale-up of China’s CGT industry, injecting fresh momentum into global life sciences advancement.